Wall Street Journal Continues Health Care Market Talk Roundups

The Wall Street Journal consistently provides roundups of market-related discussions and news within the healthcare sector, offering insights into various financial and business aspects impacting the industry, with the latest installment continuing this trend.

1 Apr, 06:48 — 2 Apr, 21:27

Post Share

Why this matters

Alkermes' stock performance and the growing interest in orexin receptor drugs highlight a potentially significant area of growth and innovation within the pharmaceutical sector. This could lead to new treatments for various conditions and impact investor strategies in the healthcare market.

Key entitiesAlkermes (ALKS)Orexin Receptor Market

The Story

What 2 sources agree on, dispute, and miss

What sources agree on

Alkermes (ALKS) stock is nearing a 52-week high
Increasing interest in orexin receptor drugs is a factor in Alkermes' performance

Key claims2 agreed

✓

Alkermes (ALKS) stock is nearing a 52-week high.

agreed·Yahoo

✓

Increasing orexin receptor market interest is contributing to Alkermes' stock performance.

agreed·Yahoo

Coverage gaps

Specific details about the orexin receptor market and its potential impact on Alkermes

ReportedYahoo

Missingwsj

The Story

Analyzing sources…

Source Diversity

Moderate (27/100)

2 sources— more sources would strengthen this score15/33

Spectrum spread— 2/5 buckets covered8/33

Far L

Left1

Left (1)

Yahoo

Center

Right1

Right (1)

wsj

Far R

Geographic diversity— 1 region4/34

US2

ℹAll sources from US region

ℹOnly 2 sources cover this story

Sources

Showing 2 of 2 sources

wsjHigh17d ago

Health Care Roundup: Market Talk - WSJ

Health Care Roundup: Market Talk WSJ

Read full article →

YahooMostly Factual18d ago

Alkermes (ALKS) Nears 52-Week High on Increasing Orexin Receptor Market Interest

Read full article →

Coverage Timeline

First report: Yahoo · 1 Apr, 06:48|Full coverage: 2 · 1d 15h|Window: 1d 15h

Left-leaningCenterRight-leaning

Yahoo1 Apr, 06:48First to report

Alkermes (ALKS) Nears 52-Week High on Increasing Orexin Receptor Market Interest

1d later

wsj2 Apr, 21:27Latest update

Health Care Roundup: Market Talk - WSJ

Story evolution

The narrative shifted from a specific focus on Alkermes' performance to its inclusion within a broader healthcare market context.

Initial ReportApr 1 morning

Yahoo Finance reports on Alkermes' stock nearing a 52-week high due to orexin receptor market interest.

Broader Market ContextApr 2 morning

The Wall Street Journal includes Alkermes' performance within a general healthcare market roundup.

PERSPECTA

PERSPECTA

Wall Street Journal Continues Health Care Market Talk Roundups

Why this matters

The Story

What sources agree on

Key claims2 agreed

Coverage gaps

The Story

Source Diversity

Source Diversity

Sources

Health Care Roundup: Market Talk - WSJ

Alkermes (ALKS) Nears 52-Week High on Increasing Orexin Receptor Market Interest

Coverage Timeline

Alkermes (ALKS) Nears 52-Week High on Increasing Orexin Receptor Market Interest

Health Care Roundup: Market Talk - WSJ

Story evolution

Related Stories

Cavite Forecasts 'Dangerous' 42°C Heat Index

Visayas Region Under 'Extreme Caution' Due to High Heat Index

Latvian Medical Research Institutes to Merge

Young Man Receives Life-Saving Liver Treatment in Romania

PERSPECTA

Why this matters

Story evolution

The Story

What sources agree on

Key claims2 agreed

Coverage gaps

Coverage matrix